Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hepatobiliary Surgery · Biliary Tract Cancer

Assembling Your Multidisciplinary Care Team

At a Glance

Because gallbladder and bile duct cancers are rare and complex, your best chance for a successful outcome is treatment at a high-volume center by a multidisciplinary team. This team should include specialized hepatobiliary surgeons, medical oncologists, and interventional radiologists.

Because gallbladder and bile duct cancers are rare and complex, they cannot be treated by a single doctor. Your best chance for a successful outcome comes from a Multidisciplinary Team (MDT)—a group of specialists who meet regularly to combine their expertise and “solve” your specific case [1][2].

The Essential Specialists

A high-functioning team for biliary tract cancer should include these core members:

  • Hepatobiliary (HPB) Surgeon: A surgeon who specializes specifically in the liver, pancreas, and bile ducts. These procedures are more complex than general surgery and require specific expertise [3][4].
  • Medical Oncologist: A doctor who manages chemotherapy, immunotherapy, and targeted treatments. They should be experienced in using Next-Generation Sequencing (NGS) to match your tumor’s genetics to the right drugs [5][6].
  • Interventional Radiologist (IR): This specialist uses advanced imaging to perform minimally invasive procedures. They are vital for placing biliary stents to drain bile and performing portal vein embolization (PVE) to help the liver grow before surgery [7][8].
  • Gastroenterologist (GI): Often the first doctor you see, they perform procedures like ERCP to take biopsies and look inside the bile ducts [3].
  • Hepatobiliary Pathologist: A specialized doctor who examines your tissue slides. Because these cancers have many “look-alikes,” having a pathologist who sees these rare cases every day is critical for an accurate diagnosis [3][9].

Non-Negotiable Imaging and Artifacts

When you go for a consultation—especially a second opinion at a major center—you must bring these “physical artifacts” with you:

  1. MRCP (Magnetic Resonance Cholangiopancreatography): This is the gold standard for seeing the “tree” of the bile ducts. It is essential for determining if a tumor can be removed [10].
  2. Multiphasic CT Scan: A high-quality CT scan taken at specific intervals (phases) as dye moves through your liver. This tells the surgeon if the cancer is touching major blood vessels [11].
  3. Pathology Slides: Do not just bring the report; bring the actual glass slides or digital images. Expert centers will want their own pathologists to “re-read” the tissue to confirm the diagnosis [11][12].

The “Volume” Rule: Why Experience Matters

Research consistently shows that patients treated at high-volume centers have better survival rates and fewer complications [13][14].

  • What is high volume? While definitions vary, many experts look for centers that perform at least 20 major biliary or pancreatic procedures per year [15][16].
  • Centralization: Complex cases are often managed through a “Hub and Spoke” model, where a patient might receive local chemotherapy but travel to a major “hub” hospital for their specialized surgery or transplant evaluation [14][17].

Vetting Your Team: 3 Essential Questions

To gauge whether your care team has the necessary experience for these rare cancers, ask these three questions:

  1. “Does this hospital have a dedicated Tumor Board that meets to discuss biliary tract cases specifically?” [1]
  2. “What is your center’s ‘R0’ resection rate for my specific type of cancer?” (This measures how often they successfully remove all the cancer) [18].
  3. “If my liver remnant is too small for surgery, does your Interventional Radiology team perform PVE to help it grow?” [8].

Common questions in this guide

What doctors should be on my biliary tract cancer care team?
Your team should include a hepatobiliary surgeon, a medical oncologist, an interventional radiologist, a gastroenterologist, and a specialized hepatobiliary pathologist. Together, they form a multidisciplinary team to manage the complexities of your specific diagnosis.
Why is it important to go to a high-volume center for gallbladder cancer?
Research shows that patients treated at high-volume centers have better survival rates and fewer complications. It is recommended to seek treatment at a center that performs at least 20 major biliary or pancreatic procedures per year.
What medical records do I need to bring for a second opinion?
You should bring the physical artifacts of your tests, including your MRCP imaging, multiphasic CT scans, and the actual glass pathology slides or digital images. Expert centers will want their own specialists to review the original materials, not just the written reports.
What is the role of an interventional radiologist in bile duct cancer?
An interventional radiologist uses advanced imaging to perform minimally invasive procedures. They are crucial for placing stents to drain blocked bile ducts and performing procedures like portal vein embolization to help the healthy part of your liver grow before surgery.
What does a multidisciplinary tumor board do?
A multidisciplinary tumor board is a group of different specialists who meet regularly to review and discuss complex cancer cases. They combine their specific expertise to create a personalized, comprehensive treatment plan for your tumor.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many cases of my specific cancer subtype (GBC, pCCA, or dCCA) do you and this hospital treat each year?
  2. 2.Will my case be reviewed by a formal multidisciplinary 'Tumor Board' that includes surgeons, oncologists, and radiologists?
  3. 3.What is the experience of your Interventional Radiology (IR) team with procedures like portal vein embolization (PVE) and biliary stenting?
  4. 4.Do you have a specialized hepatobiliary pathologist on staff who routinely reviews bile duct and gallbladder tissue?
  5. 5.Based on my scans, do you consider me a candidate for surgery now, or should we use neoadjuvant therapy first to improve the chances of a successful R0 resection?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Biliary tract cancer.

    Søreide K, Dopazo C, Berrevoet F, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2025; (51(6)):108489 doi:10.1016/j.ejso.2024.108489.

    PMID: 38902180
  2. 2

    Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged.

    Alabraba E, Joshi H, Bird N, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019; (45(9)):1660-1667 doi:10.1016/j.ejso.2019.04.002.

    PMID: 31014988
  3. 3

    Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?

    Ricci AD, Rizzo A

    Medicina (Kaunas, Lithuania) 2021; (57(12)) doi:10.3390/medicina57121301.

    PMID: 34946246
  4. 4

    Short-term and long-term outcomes of hepatopancreatoduodenectomy for extrahepatic cholangiocarcinoma and gallbladder carcinoma: A systematic review and meta-analysis with meta-regression.

    Hajibandeh S, Hajibandeh S, Raza SS, et al.

    Surgery 2025; (186()):109593 doi:10.1016/j.surg.2025.109593.

    PMID: 40782723
  5. 5

    NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.

    Benson AB, D'Angelica MI, Abrams T, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(7)):694-704 doi:10.6004/jnccn.2023.0035.

    PMID: 37433432
  6. 6

    Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers.

    Okamura R, Kurzrock R, Mallory RJ, et al.

    International journal of cancer 2021; (148(3)):702-712 doi:10.1002/ijc.33230.

    PMID: 32700810
  7. 7

    Preoperative Management of Perihilar Cholangiocarcinoma.

    Ellis RJ, Soares KC, Jarnagin WR

    Cancers 2022; (14(9)) doi:10.3390/cancers14092119.

    PMID: 35565250
  8. 8

    ASO Author Reflections: Essential to Reduce Adverse Outcomes in Perihilar Cholangiocarcinoma Surgery-Portal Vein Embolization.

    Olthof PB, van Gulik TM

    Annals of surgical oncology 2020; (27(7)):2319-2320 doi:10.1245/s10434-020-08333-9.

    PMID: 32152772
  9. 9

    Practice patterns in diagnostics, staging, and management strategies of gallbladder cancer among Nordic tertiary centers.

    Takala S, Lassen K, Søreide K, et al.

    Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 2023; (112(3)):147-156 doi:10.1177/14574969231181228.

    PMID: 37377127
  10. 10

    Investigation of the accuracy of magnetic resonance cholangiography and multi-slice spiral computed tomography in the diagnosis of cholangiocarcinoma.

    Ke C, Yang T, Huang G, Gu C

    Journal of gastrointestinal oncology 2023; (14(3)):1496-1503 doi:10.21037/jgo-22-1294.

    PMID: 37435202
  11. 11

    Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications.

    Lee SH, Song SY

    Cancers 2024; (16(9)) doi:10.3390/cancers16091761.

    PMID: 38730713
  12. 12

    Leveraging Multimodal Foundation Models in Biliary Tract Cancer Research.

    Singh Y, Andersen JB, Hathaway QA, et al.

    Tomography (Ann Arbor, Mich.) 2025; (11(9)) doi:10.3390/tomography11090096.

    PMID: 41003479
  13. 13

    Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies.

    Elshami M, Ahmed FA, Hue JJ, et al.

    Surgery 2023; (173(2)):289-298 doi:10.1016/j.surg.2022.10.011.

    PMID: 36402613
  14. 14

    Trends in hospital volume and operative mortality in hepato-biliary surgery in Veneto region, Italy.

    Guglielmi A, Tripepi M, Salmaso L, et al.

    Updates in surgery 2023; (75(7)):1949-1959 doi:10.1007/s13304-023-01574-9.

    PMID: 37395932
  15. 15

    Volume-outcome relationship of liver surgery: a nationwide analysis.

    Olthof PB, Elfrink AKE, Marra E, et al.

    The British journal of surgery 2020; (107(7)):917-926 doi:10.1002/bjs.11586.

    PMID: 32207856
  16. 16

    The volume-outcome relationship for pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.

    Heuts S, Kawczynski MJ, Leus A, et al.

    The European respiratory journal 2025; (65(2)) doi:10.1183/13993003.01865-2024.

    PMID: 39572220
  17. 17

    Hospital Surgical Volume and 3-Year Mortality in Severe Prognosis Cancers: A Population-Based Study Using Cancer Registry Data.

    Taniyama Y, Tabuchi T, Ohno Y, et al.

    Journal of epidemiology 2021; (31(1)):52-58 doi:10.2188/jea.JE20190242.

    PMID: 31932528
  18. 18

    Gallbladder Cancer: Diagnosis, Surgical Management, and Adjuvant Therapies.

    Hickman L, Contreras C

    The Surgical clinics of North America 2019; (99(2)):337-355 doi:10.1016/j.suc.2018.12.008.

    PMID: 30846038

This guide to assembling a multidisciplinary care team is for informational purposes only. Always consult with qualified oncology specialists to determine the best care facility and treatment plan for your specific diagnosis.

Get notified when new evidence is published on Carcinoma of gallbladder and extrahepatic biliary tract.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.